pifithrin has been researched along with Hyperlipoproteinemia Type II in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashiwakura, Y | 1 |
| Watanabe, M | 1 |
| Kusumi, N | 1 |
| Sumiyoshi, K | 1 |
| Nasu, Y | 1 |
| Yamada, H | 1 |
| Sawamura, T | 1 |
| Kumon, H | 1 |
| Takei, K | 1 |
| Daida, H | 1 |
1 other study available for pifithrin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Dynamin-2 regulates oxidized low-density lipoprotein-induced apoptosis of vascular smooth muscle cell.
Topics: Animals; Apolipoproteins E; Apoptosis; Benzothiazoles; Coronary Vessels; Dynamin II; Endocytosis; Hu | 2004 |